Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85:174–180

Google Scholar 

Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Engl J Med 346:995–1008

Article  Google Scholar 

Kohli R, Chaturvedi S (2019); 39:238–249

Bidika E, Fayyaz H, Salib M, Memon AN, Gowda AS, Rallabhandi B, Cancarevic I (2020) Romiplostim and Eltrombopag in Immune Thrombocytopenia as a second-line treatment. Cureus 12:e9920

Google Scholar 

Meletis J, Katsandris A, Raptis SD, Mantzourani M (2010) Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim. Med Sci Monit 16:CS100–CS102

Google Scholar 

Kim TO, Despotovic J, Lambert MP (2018) Eltrombopag for use in children with immune thrombocytopenia. Blood Adv 2:454–461

Article  CAS  Google Scholar 

Gonzalez-Porras JR, Bastida JM (2018) Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Ther Adv Drug Saf 9:263–285

Article  CAS  Google Scholar 

Panzer S, Hocker L, Rieger M, Vormittag R, Koren D, Dunkler D, Pabinger I (2007) Agonist-inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia. Eur J Haematol 79:198–204

Article  CAS  Google Scholar 

Harker LA (1998) Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol 35:241–252

CAS  Google Scholar 

Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD (2012) In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 119:4066–4072

Article  CAS  Google Scholar 

Gardiner EE, Andrews RK (2014) Platelet receptor expression and shedding: glycoprotein Ib-IX-V and glycoprotein VI. Trans Med Rev 28:56–60

Article  Google Scholar 

Yun SH, Sim EH, Goh RY, Park JI, Han JY (2016) Platelet activation: the Mechanisms and potential biomarkers. BioMed Res Int; 1–5

Holmes ML, Bartle N, Eisbacher M, Chong BH (2002) Cloning and analysis of the thrombopoietin-induced megakaryocyte-specific glycoprotein VI promoter and its regulation by GATA-1, Fli-1, and Sp1. J Biol Chem 277:48333–48341

Article  CAS  Google Scholar 

Kanaji S, Kanaji T, Jacquelin B, Chang M, Nugent DJ, Komatsu N, Moroi M, Izuhara K, Kunicki TJ (2005) Thrombopoietin initiates demethylation-based transcription of GP6 during megakaryocyte differentiation. Blood 105:3888–3892

Article  CAS  Google Scholar 

Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, Valoret EI, Duffy KJ, Luengo JL, Rosen J, Miller SG (2005) Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 33:85–93

Article  CAS  Google Scholar 

Page LK, Psaila B, Provan D, Michael Hamilton J, Jenkins JM, Elish AS, Lesser ML, Bussel JB (2007) The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol 138:245–248

Article  Google Scholar 

Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152:726–732

Article  Google Scholar 

Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373(9664):641–648

Article  CAS  Google Scholar 

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393

Article  CAS  Google Scholar 

Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, Kühne T (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3:3829–3866

Article  CAS  Google Scholar 

Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK (2015) Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2:e315–e257

Article  Google Scholar 

Bussel JB, Mahmud SN, Brigstocke SL, Torneten SM (2015) Tapering eltrombopag in patients with chronic ITP: how successful is this and in whom does it work? Blood 126:1054

Article  Google Scholar 

Klaassen RJ, Blanchette VS, Barnard D, Wakefield CD, Curtis C, Bradley CS, Neufeld EJ, Buchanan GR, Silva MP, Chan AK, Young NL (2007) Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids’ ITP Tools. J Pediatr 150:510–515

Article  Google Scholar 

Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H, Schonberger T, Kremmer E, Siegel-Axel D, May AE, Gawaz M (2006) Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 27:2165–2169

Article  CAS  Google Scholar 

Bigalke B, Stellos K, Stakos D, Joos T, Pötz O, Geisler T, Bischofs C, Kremmer E, Krämer BF, Seizer P, May AE (2009) Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome. Thromb Haemost 101:911–915

Article  CAS  Google Scholar 

Massberg S, Konrad I, Bültmann A, Schulz C, Münch G, Peluso M, Lorenz M, Schneider S, Besta F, Müller I, Hu B (2004) Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 18:397–399

Article  CAS  Google Scholar 

Laske C, Leyhe T, Stransky E, Eschweiler GW, Bueltmann A, Langer H, Stellos K, Gawaz M (2008) Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer’s disease. J Psychiatr Res 42:746–751

Article  Google Scholar 

Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386:1649–1658

Article  CAS  Google Scholar 

Giordano P, Lassandro G, Barone A, Cesaro S, Fotzi I, Giona F, Ladogana S, Miano M, Marzollo A, Nardi M, Notarangelo LD (2020) Use of Eltrombopag in Children with Chronic Immune Thrombocytopenia (ITP): a Real Life Retrospective Multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Front Med (Lausanne) 7:661–667

Google Scholar 

Chen M, Fang JP, Zhou CX, Li XY, Lin SF, Xu LH (2021) Efficacy and safety of eltrombopag in the treatment of chinese children with chronic immune thrombocytopenia. Hematol 26:31–36

Article  CAS  Google Scholar 

Sestøl HG, Trangbæk SM, Bussel JB, Frederiksen H (2018) Health-related quality of life in adult primary immune thrombocytopenia. Expert Rev Hematol 11:975–985

Article  Google Scholar 

Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM (2019) Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. Am J Hematol 94:741–750

CAS  Google Scholar 

Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB (2019) Health related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. Br J Haematol 185:102–106

Article  CAS  Google Scholar 

Gardiner EE, Al-Tamimi M, Mu FT, Karunakaran D, Thom JY, Moroi M, Andrews RK, Berndt MC, Baker RI (2008) Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost 6:1175–1182

Article  CAS  Google Scholar 

Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK (2009) Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 20:143–149

Article  CAS  Google Scholar 

Andrews RK, Arthur JF, Gardiner EE (2014) Targeting GPVI as a novel antithrombotic strategy. J Blood Med 5:59–68

CAS  Google Scholar 

Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman KD, Curtis BR, Stapleton M, Newman DK, Kahn ML, Newman PJ (2004) Anti- GPVI-associated ITP: an acquired platelet disorder caused by autoantibody- mediated clearance of the GPVI/FcRc-chain complex from the human platelet surface. Blood 104:1350–1355

Article  CAS  Google Scholar 

Chiou TJ, Chang YF, Wang MC, Kao CW, Lin HY, Chen TY, Hsueh EJ, Lan YJ, Sung YC, Lin SF, Bai LY (2015) Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura. Transl Res 166:750–776

Article  CAS  Google Scholar 

Haselboeck J, Pabinger I, Ay C, Koder S, Panzer S (2012) Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. Ann Hematol 91:109–113

Article  CAS  Google Scholar 

Ignatova AA, Demina IA, Ryabykh AA, Obydennyi SI, Polokhov DM, Seregina EA, Poletaev AV, Ataullakhanov FI, Maschan AA, Novichkova GA, Panteleev MA (2019) Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment. Br J Haematol 187:e38–42

Article  Google Scholar